Here are relevant reports on : oncology-drugs-market
-
Global Weight Loss Drugs, Supplements And Cosmetics Market
Individuals with high BMI have a greater risk of developing diseases such as cancer and diabetes. This holds true for both men and women; and those with BMI above 35 are at the highest risk. However, increasing awareness about obesity is encouraging consumers to seek medical assistance and consultation for weight reduction. The market for weight-loss drugs, cosmetics, and supplements is witnessing a significant growth as these do not involve strict diet or exercise regimens. Top pharmaceutical companies have thus increased R&D investments for anti-obesity drugs with minimal or no side effects.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
COVID-19 Impact on Vaccines & Drugs Market - Global Forecast to 2025
The COVID-19 vaccines & drugs market is expected to grow from USD 2,273 million in 2022 to USD 1,401 million by 2025 at a compound annual growth rate (CAGR) of 14.9% during the forecast period.Key players in the COVID-19 vaccines market include Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) among others.
- Published: May 2020
- Price: $ 4950
- TOC Available:
-
Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, stood at US$145.53 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$246.66 billion by the end of the period. Factors such as the growing integration of AI and ML to enhance precision diagnostics and medicine development supported by rising collaborations between pharmaceutical and diagnostics companies to improve precision healthcare and the rise in direct-to-consumer testing are driving the growth in the market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028
The global RNA therapeutics market, valued at US$32.2 billion in 2022, stood at US$13.7 billion in 2023 and is projected to advance at a resilient CAGR of 5.6% from 2023 to 2028, culminating in a forecasted valuation of US$18.0 billion by the end of the period. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User—Global Forecast to 2031
The global veterinary pharmaceuticals market, valued at USD 27.41 billion in 2025, stood at USD 28.98 billion in 2026 and is projected to advance at a resilient CAGR of 6.3% from 2026 to 2031, culminating in a forecasted valuation of USD 39.37 billion by the end of the period. The market growth is driven by rising pet ownership, increasing livestock production, and higher demand for disease management drugs. Expanding awareness of animal health, growing expenditure on companion animals, and advancements in anti-infectives, parasiticides, and dermatology treatments are further supporting steady market expansion across developed and emerging regions.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Skin Cancer Drugs Market by Type (Chemotherapy, Immunotherapy), Disease Indication (Melanoma, Basal and Squamous), Distribution Channel – Global Forecast to 2027
The global skin cancer drugs market is projected to reach USD ~6 billion by 2027 from USD 4 billion in 2022, at a CAGR of 9 % during the forecast period
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Antipsychotic Drugs Market by Therapeutic Class (First Generation, Second Generation, Third Generation), Drug (Aripiprazole, Brexipiprazole, Risperidone), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Forecast to 2027
The global antipsychotic drugs market is projected to reach USD ~25 billion by 2027 from USD 14 billion in 2022, at a CAGR of 8% between 2022 and 2027.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Women's Healthcare Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) & Region - Global Forecast to 2024
The global women's healthcare market growth is primed to transition from $9.6 billion in 2019 to $17.8 billion by 2024, showcasing a strong CAGR of 13.2%. Key drivers of this growth include increasing chronic health conditions among women, government initiatives for population control, and rising demand for contraceptives.
- Published: January 2020
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
